Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) has received a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have covered the stock in the last year is $34.50.
Separately, HC Wainwright reissued a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Monday.
View Our Latest Research Report on CAPR
Capricor Therapeutics Stock Performance
Hedge Funds Weigh In On Capricor Therapeutics
Large investors have recently bought and sold shares of the stock. Oppenheimer & Co. Inc. raised its holdings in Capricor Therapeutics by 25.2% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company’s stock valued at $1,040,000 after acquiring an additional 13,762 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Capricor Therapeutics in the third quarter valued at $161,000. FMR LLC bought a new position in Capricor Therapeutics in the third quarter worth $370,000. BNP Paribas Financial Markets boosted its stake in Capricor Therapeutics by 868.7% during the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after buying an additional 15,872 shares in the last quarter. Finally, Fred Alger Management LLC acquired a new stake in Capricor Therapeutics during the third quarter worth $399,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Read More
- Five stocks we like better than Capricor Therapeutics
- How Investors Can Find the Best Cheap Dividend Stocks
- Can TikTok Stock Picks Really Make You Rich?
- With Risk Tolerance, One Size Does Not Fit All
- The “Quality” Rotation: Back to Basics Investing
- What is Insider Trading? What You Can Learn from Insider Trading
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.